These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 667367)

  • 1. Antithrombogenicity of immobilized urokinase and its clinical significance.
    Sugitachi A; Kawahara T; Kodama J; Kikkawa Y; Takagi K
    Blut; 1978 Jul; 37(1):31-6. PubMed ID: 667367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antithrombogenicity of UK-immobilized polymer surfaces.
    Sugitachi A; Tanaka M; Kawahara T; Takagi K
    Trans Am Soc Artif Intern Organs; 1980; 26():274-8. PubMed ID: 7018054
    [No Abstract]   [Full Text] [Related]  

  • 3. Immobilization of plasminogen activator, urokinase, on nylon.
    Sugitachi A; Takagi K; Imaoka S; Kosaki G
    Thromb Haemost; 1978 Apr; 39(2):426-36. PubMed ID: 580991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urokinase immobilized on medical polymeric materials: fundamental and clinical studies.
    Ohshiro T; Kosaki G
    Artif Organs; 1980 Feb; 4(1):58-4. PubMed ID: 6989347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antithrombogenicity of immobilized urokinase--clinical application.
    Sugitachi A; Takagi K
    Int J Artif Organs; 1978 Mar; 1(2):88-92. PubMed ID: 681005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacology of fibrinolytics].
    Klöcking HP
    Z Gesamte Inn Med; 1979 Jan; 34(1):22-8. PubMed ID: 373275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Changes in the components of the animal fibrinolytic system induced by the action of physiological activators and enzymes of fungal origin].
    Andreenko GV; Serebriakova TN; Shimonaeva EE; Liutova LV; Karabasova MA
    Nauchnye Doki Vyss Shkoly Biol Nauki; 1983; (3):51-4. PubMed ID: 6342687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
    Matsuo O; Rijken DC; Collen D
    Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of dextran on the fibrinolytic activity of urokinase.
    Matsuo O; Kosugi T; Mihara H
    Nihon Ketsueki Gakkai Zasshi; 1982 Feb; 45(1):112-8. PubMed ID: 6180584
    [No Abstract]   [Full Text] [Related]  

  • 10. Fibrinolytic activity of immobilized plasminogen activator.
    Senatore FF; Bernath FR
    Res Commun Chem Pathol Pharmacol; 1985 Aug; 49(2):295-304. PubMed ID: 4059655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Substrate composition and the effect of epsilon-aminocaproic acid on tissue plasminogen activator and urokinase-induced fibrinolysis.
    Thorsen S; Astrup T
    Thromb Diath Haemorrh; 1974 Dec; 32(2-3):306-24. PubMed ID: 4281113
    [No Abstract]   [Full Text] [Related]  

  • 12. [Experimental studies on thrombolytic agents. (1) Comparison between prostaglandin E1, heparin and urokinase (author's transl)].
    Suzuki T; Takano S
    Nihon Ketsueki Gakkai Zasshi; 1978 Oct; 41(5):890-6. PubMed ID: 735704
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparative study of different urokinase preparations.
    Millar WT; Smith JF
    Thromb Res; 1983 Jun; 30(5):425-9. PubMed ID: 6351343
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vasodilation due to urokinase in the canine femoral circulation.
    Gurll NJ; Zinner MJ; Callahan W; Reynolds DG
    J Pharmacol Exp Ther; 1977 Jun; 201(3):731-7. PubMed ID: 864605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of urokinase on fibrinolysis and fibrinogenolysis.
    Matsuo O; Nishida Y; Akazawa K; Mihara H
    Jpn J Physiol; 1982; 32(5):879-83. PubMed ID: 6759739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergism of tissue-type plasminogen activator (t-PA) and single-chain urokinase-type plasminogen activator (scu-PA) on clot lysis in vitro and a mechanism for this effect.
    Gurewich V; Pannell R
    Thromb Haemost; 1987 Jun; 57(3):372-3. PubMed ID: 3116707
    [No Abstract]   [Full Text] [Related]  

  • 17. [Heparin and urokinase interactions in the fibrinolytic system].
    Villaverde CA; Badimón L; Badimón JJ; Valdecasas FG
    Arch Farmacol Toxicol; 1979 Dec; 5(3):268-9. PubMed ID: 397804
    [No Abstract]   [Full Text] [Related]  

  • 18. Catalytic and fibrinolytic properties of recombinant urokinase plasminogen activator from E. coli, mammalian, and yeast cells.
    Wang P; Zhang J; Sun Z; Chen Y; Gurewich V; Liu JN
    Thromb Res; 2000 Dec; 100(5):461-7. PubMed ID: 11150590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of intrathecally administered urokinase, tissue-type plasminogen activator, and combination of urokinase and lysine-plasminogen for clot lysis after experimental subarachnoid hemorrhage in dogs.
    Kajimoto Y; Ohta T; Kuroiwa T
    Neurosurgery; 1997 Mar; 40(3):572-7. PubMed ID: 9055298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urokinase immobilized on erythrocytes.
    Kitao T; Hattori K
    Thromb Haemost; 1980 Feb; 43(1):70. PubMed ID: 6996207
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.